Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Henry A Nasrallah

Showing results (1-10 of 150) with videos related to

Pageof 15
Sort By:
CNS Spectrums|July 4, 2006
Metabolic findings from the CATIE trial and their relation to tolerabilityHenry A Nasrallah
CNS Spectrums|October 22, 2008
The urgent need for monitoring and intervention to reduce metabolic risk factors in patients with schizophreniaHenry A Nasrallah
Schizophrenia Research|February 24, 2009
Meta-analysis trends in schizophrenia over three decadesHenry A Nasrallah
Asian Journal of Psychiatry|September 23, 2015
Toward the era of transformational neuropsychiatryHenry A Nasrallah
Annals of Clinical Psychiatry : Official Journal of the American Academy of Clinical Psychiatrists|August 16, 2021
Re-inventing the DSM as a transdiagnostic model: Psychiatric disorders are extensively interconnectedHenry A Nasrallah
Schizophrenia Research|January 28, 2023
Is preventing the second psychotic episode a disease-modifying strategy for schizophrenia?Henry A Nasrallah
The Journal of Clinical Psychiatry|November 4, 2015
Consequences of misdiagnosis: inaccurate treatment and poor patient outcomes in bipolar disorderHenry A Nasrallah
CNS Spectrums|February 24, 2004
Factors in antipsychotic drug selection: tolerability considerationsHenry A Nasrallah
Schizophrenia Research|March 7, 2018
Triple advantages of injectable long acting second generation antipsychotics: Relapse prevention, neuroprotection, and lower mortalityHenry A Nasrallah
The Journal of Clinical Psychiatry|August 19, 2005
Neurologic comorbidities in schizophreniaHenry A Nasrallah
Pageof 15

Showing results (1-10 of 150) with videos related to

Sort By:
Pageof 15
CNS Spectrums|July 4, 2006
Metabolic findings from the CATIE trial and their relation to tolerabilityHenry A Nasrallah
CNS Spectrums|October 22, 2008
The urgent need for monitoring and intervention to reduce metabolic risk factors in patients with schizophreniaHenry A Nasrallah
Schizophrenia Research|February 24, 2009
Meta-analysis trends in schizophrenia over three decadesHenry A Nasrallah
Asian Journal of Psychiatry|September 23, 2015
Toward the era of transformational neuropsychiatryHenry A Nasrallah
Annals of Clinical Psychiatry : Official Journal of the American Academy of Clinical Psychiatrists|August 16, 2021
Re-inventing the DSM as a transdiagnostic model: Psychiatric disorders are extensively interconnectedHenry A Nasrallah
Schizophrenia Research|January 28, 2023
Is preventing the second psychotic episode a disease-modifying strategy for schizophrenia?Henry A Nasrallah
The Journal of Clinical Psychiatry|November 4, 2015
Consequences of misdiagnosis: inaccurate treatment and poor patient outcomes in bipolar disorderHenry A Nasrallah
CNS Spectrums|February 24, 2004
Factors in antipsychotic drug selection: tolerability considerationsHenry A Nasrallah
Schizophrenia Research|March 7, 2018
Triple advantages of injectable long acting second generation antipsychotics: Relapse prevention, neuroprotection, and lower mortalityHenry A Nasrallah
The Journal of Clinical Psychiatry|August 19, 2005
Neurologic comorbidities in schizophreniaHenry A Nasrallah
Pageof 15